Eli Lilly and Company announced its second-quarter 2025 financial results, reporting a 38% increase in revenue to $15.56 billion. This growth was primarily driven by volume increases in key products Zepbound and Mounjaro. The company saw a significant rise in earnings per share $(EPS)$, which increased by 92% to $6.29 on a reported basis and by 61% to $6.31 on a non-GAAP basis. Looking ahead, Eli Lilly has raised its full-year 2025 revenue guidance, increasing the midpoint by $1.5 billion to a range of $60 billion to $62 billion. The reported EPS guidance has been revised to a range of $20.85 to $22.10, while the non-GAAP EPS guidance is now projected to be between $21.75 and $23.00. In terms of business development, the company completed the acquisitions of SiteOne Therapeutics, Inc. and Verve Therapeutics, Inc. Additionally, Eli Lilly's pipeline showed progress with positive results in studies related to orforglipron for obesity, Mounjaro SURPASS CVOT for type 2 diabetes and heart disease, and Jaypirca H2H versus Imbruvica in CLL/SLL.